X0508 4 2024-03-20 0 0001658247 Crinetics Pharmaceuticals, Inc. CRNX 0001397266 Fust Matthew K C/O CRINETICS PHARMACEUTICALS, INC. 6055 LUSK BOULEVARD SAN DIEGO CA 92121 1 0 0 0 1 Common Stock 2024-03-20 4 M 0 12500 23.24 A 31036 D Common Stock 2024-03-20 4 S 0 12500 43.57 D 18536 D Common Stock 2024-03-20 4 M 0 12500 23.23 A 31036 D Common Stock 2024-03-20 4 S 0 12500 43.57 D 18536 D Common Stock 2024-03-20 4 M 0 17500 20.23 A 36036 D Common Stock 2024-03-20 4 S 0 17500 43.58 D 18536 D Common Stock 2024-03-20 4 M 0 17500 18.29 A 36036 D Common Stock 2024-03-20 4 S 0 17500 45.50 D 18536 D Stock Option (right to buy) 23.24 2024-03-20 4 M 0 12500 0.00 A 2029-06-20 Common Stock 12500 0 D Stock Option (right to buy) 23.23 2024-03-20 4 M 0 12500 0.00 A 2030-06-18 Common Stock 12500 0 D Stock Option (right to buy) 20.23 2024-03-20 4 M 0 17500 0.00 A 2031-06-21 Common Stock 17500 0 D Stock Option (right to buy) 18.29 2024-03-20 4 M 0 17500 0.00 A 2032-06-16 Common Stock 17500 0 D The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.57 per share. The range of sales prices on the transaction date was $42.70 to $44.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $43.58 per share. The range of sales prices on the transaction date was $42.70 to $44.23 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request. The stock option shall vest and become exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next occurring annual meeting of the Issuer's stockholders, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date. /s/ Marc Wilson, as attorney-in-fact 2024-03-22